| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8629686 | Diabetes Research and Clinical Practice | 2018 | 7 Pages |
Abstract
Ramadan fasting was associated with significant changes in weight, BP and eGFR regardless whether patients were on SGLT2 inhibitor treatment. Continued use of SGLT2 Inhibitors during Ramadan did not increase ketonemia, nor increase risk of eGFR deterioration and hypoglycaemia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Yanli Shao, Gwyneth Joy Lim, Chin Lian Chua, Yip Fong Wong, Ester Chai Kheng Yeoh, Serena Kiat Mun Low, Chee Fang Sum,